Additionally, the serum DANCR expression level in patients after surgery or chemotherapy treatment decreased significantly to a level similar to that in the healthy controls, but rebounded in cases of tumor recurrence, suggesting that serum DANCR could be used to monitor disease progression and predict prognosis of CRC patients. This evidence concerns the gene DANCR and neoplasm.